×

Our Research

Sandra Redmond

  • Murphy A, Redmond S. To HTA or Not to HTA: Identifying the Factors Influencing the Rapid Review Outcome in Ireland. Value in Health. 2019;22(4):385-90. Download
  • Murphy A, Redmond S. Rapid Reviews with Health-Technology Assessments in Reimbursement Systems – an Examination of Ireland as a Case Study. 2017;4(1):grhta.5000250. Download
  • Wong B, Redmond S., O’Neill J. Iron deficiency in Patients with Heart Failure; Prevalence and Budget Impact. Forthcoming. Download
  • Nolan JJ, O’Halloran D, McKenna TJ, Firth R, Redmond S. The cost of treating type 2 diabetes (CODEIRE). Ir Med J. 2006 Nov-Dec;99(10):307-10. Download

Dr. Raymond Henderson

  • Henderson RH, French D, Maughan T, Adams R, Allemani C, Minicozzi P, Coleman MP, McFerran E, Sullivan R, Lawler M. The economic burden of colorectal cancer across Europe: a population-based cost-of-illness study. The Lancet Gastroenterology & Hepatology. 2021 Jul 28. Download
  • Henderson R., Keeling P, French D, Smart D, Sullivan R, Lawler M. Cost‐effectiveness of precision diagnostic testing for precision medicine approaches against non‐small‐cell lung cancer: a systematic review. Molecular Oncology. 2021 Jun 10. Download
  • Henderson, R., French, D., Sullivan, R., Maughan, T., Clarke, M., & Lawler, M. (2019). Molecular biomarkers and precision medicine in colorectal cancer: a systematic review of health economic analyses. Oncotarget 10:3408-3423. Download
  • Henderson, R., O’Kane, M., McGilligan, V. and Watterson, S., 2016. The genetics and screening of familial hypercholesterolemia. Journal of Biomedical Science, 23(1), 39-51. Download
  • Henderson, R., Smart, D., French, D., Clark, J., Bloom, K. J., Hosty, D., and Lawler, M. (2020). Economic burden of not testing for FLT3 to treat acute myeloid leukemia. American Society for Clinical Oncology, Chicago (Abstract). Read here
  • Henderson, R., French, D., Stewart, E., Smart, D., Idica, A., Redmond, S., Eckstein, M., Clark, J., Sullivan, R., Keeling, P. and Lawler, M. (2023). Delivering the precision oncology paradigm: reduced R&D costs and greater return on investment through a companion diagnostic informed precision oncology medicines approach. Journal of Pharmaceutical Policy and Practice 16:84. Download
  • Henderson, R., French, D., McFerran, E., Adams, R., Wasan, H., Glynne-Jones, R., Fisher, D., Richman, S., Dunne, P.D., Wilde, L., Maughan, T.S., Sullivan, R., Lawler, M. (2022). Spend less to achieve more: Economic analysis of intermittent versus continuous cetuximab in KRAS wild-type patients with metastatic colorectal cancer. Journal of Cancer Policy (33). Download

Other Publications

  • Easing The Economic Burden Of Asthma: The Impact of a Universal Asthma Self-Management Programme (June 2019). Download

Conference Presentations: Explore Our Posters

  • Precision versus non-precision oncology drug submissions to the National Centre for Pharmacoeconomics in Ireland (ISPOR 2022). Download
  • Association of NCPE Submission Outcomes in Ireland with Additional Benefit Rating in Germany (ISPOR 2022). Download
  • Association of NCPE Submission Outcomes in Ireland with Added Therapeutic Value (ASMR) Rating in France (ISPOR 2022). Download
  • Factors affecting time to reimbursement of novel anticancer drugs in Ireland (ISPOR 2023). Download
  • The economic burden that Respiratory Syncytial Virus (RSV) imposes on Irish hospitals (ISPOR 2023). Download
  • The increasing incidence of Respiratory Syncytial Virus (RSV) in Ireland (ISPOR 2023). Download
  • Time to Reimbursement of Novel Anticancer Drugs in Ireland Compared to Six European Countries and the UK (ISPOR 2023). Download